Progression-free survival. Blue solid lines indicate patients with lymphoma that responded to mosunetuzumab (complete response/partial response; responder), and red dashed lines indicate patients with lymphoma that did not respond to mosunetuzumab (stable disease/progressive disease; nonresponder). (A) Progression-free survival for the entire cohort (N = 30). (B) Progression-free survival all patients (N = 30) based on response to mosunetuzumab. (C) Progression-free survival for patients with large B-cell lymphomas (n = 27). (D) Progression-free survival for patients with large B-cell lymphomas (n = 27) based on response to mosunetuzumab.